Vaccine News and Research

Latest Vaccine News and Research

LANL and international researchers propose new genome sequence strategies

A team of geneticists at Los Alamos National Laboratory, together with a consortium of international researchers, has recently proposed a set of standards designed to elucidate the quality of publicly available genetic sequencing information.

22 Oct 2009

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.

22 Oct 2009

GlaxoSmithKline's CERVARIX recommended by CDC for protection against cervical cancer

GlaxoSmithKline announced today that the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) recommended that CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] be given to girls and young women to protect against cervical pre-cancers and cervical cancer caused by oncogenic HPV 16 and 18.

22 Oct 2009

Media outlets examine how AIDS vaccine trial results will shape future studies

As the AIDS vaccine conference continues in Paris this week, Reuters examines how recent trials are helping researchers better understand ways to develop a vaccine that offers people protection from HIV.

22 Oct 2009

Women more likely than men to curb swine flu

A new American Red Cross poll shows that while concerns about exposure to the H1N1 (swine flu) virus remain high, women are more likely than men to make extra efforts to cover coughs and sneezes with tissue, wash their hands more carefully and use hand sanitizer more often.

22 Oct 2009

AIDS vaccine not as effective as first thought, scientists say

A vaccine to protect against HIV may not be as effective as first thought, scientists said Tuesday.

22 Oct 2009

106m infants worldwide received vaccines last year, coverage gaps remain, report says

A joint report by the WHO, UNICEF and the World Bank on worldwide vaccination efforts released Wednesday found "a record 106 million infants were vaccinated last year against life-threatening diseases, but nearly a fifth of the world's babies still are not protected fully," the Associated Press reports.

22 Oct 2009

Research suggests latent cytomegalovirus infection exacerbates inflammatory bowel disease

Current research suggests that latent cytomegalovirus (CMV) infection may exacerbate inflammatory bowel disease (IBD). The related report by Onyeagocha et al, "Latent cytomegalovirus infection exacerbates experimental colitis," appears in the November 2009 issue of The American Journal of Pathology.

21 Oct 2009

EMEA informs Antigenics on a negative opinion for Oncophage MAA

Antigenics Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMEA), has verbally informed the Company at an oral meeting to anticipate a negative opinion on the marketing authorization application (MAA) for Oncophage (vitespen) in early-stage, localized renal cell carcinoma (kidney cancer).

21 Oct 2009

Positive results from Argos Therapeutics' personalized immunotherapy candidate AGS-004 Phase 2a trial

Argos Therapeutics today announced two presentations at the AIDS Vaccine 2009 conference, detailing positive viral load, immune response and safety data from an ongoing Phase 2a trial of AGS-004, its personalized immunotherapy candidate. AGS-004 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded, dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden.

21 Oct 2009

Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain

Northwest Biotherapeutics, Inc. today announced further long-term follow-up data, for the period from January through September 2009, from its prior Phase I and Phase I/II clinical trials conducted at UCLA with DCVax®-Brain in patients with Glioblastoma multiforme ("GBM"). GBM is the most rapid and lethal type of brain cancer. During the update period, only one of the twenty patients treated with DCVax®-Brain (in addition to standard of care) died, and that patient had survived for nearly 7 years (80.5 months).

21 Oct 2009

Swine flu vaccines arrive at health departments, hospitals and community vaccinator facilities

The Swine Flu (H1N1)Vaccine is starting to arrive at health departments, hospitals, and community vaccinator facilities.

21 Oct 2009

Novavax, Xcellerex enter into collaboration to accelerate the development of Novavax's 2009 H1N1 vaccine

Novavax, Inc. and Xcellerex, Inc. have entered into a strategic collaboration to accelerate the development of Novavax's vaccine manufacturing process to commercial scale and begin immediate production of Novavax's novel 2009 H1N1 influenza vaccine for potential commercial sale.

21 Oct 2009

Professor secures grant for further research on immunotherapy strategies

Venuprasad K. Poojary, Ph.D., assistant professor at the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, has secured a two-year federal grant for almost $1 million to further his research into creating more effective immunotherapy strategies for cancer treatment.

21 Oct 2009

Aethlon Hemopurifier effective in capturing H1N1 Swine Flu Virus

Aethlon Medical, Inc. announced today that research studies have documented the Aethlon Hemopurifier® is effective in capturing the current pandemic strain of the H1N1 Swine Flu Virus. The Hemopurifier® is the first-in-class medical device able to selectively remove infectious viruses and immunosuppressive proteins from the bloodstream.

21 Oct 2009

Weekly Digest releases report on investment opportunities in connection with the H1N1 outbreak

Weekly Digest (http://www.bullmarket.com/digest), a free investment research publication, announced the publication of a special report on investment opportunities in connection with the H1N1 "Swine Flu" Outbreak, including updated outlooks for GlaxoSmithKline, Sanofi-Aventis, Novartis, Baxter International, Roche Holding and several others.

21 Oct 2009

New public health tool to identify all Tier 1 candidates for H1N1 vaccination

Practice Fusion Inc. (www.practicefusion.com), the free, web-based electronic health record (EHR) for physicians, today implemented a first-of-its-kind tool that allows its physician-users to immediately and accurately identify all Tier 1 candidates for H1N1 vaccination from their patient populations using criteria published by the Centers for Disease Control and Prevention (CDC).

21 Oct 2009

Elan announces fiscal 2009 third-quarter results

Elan Corporation, plc today reported its third quarter 2009 financial results.

21 Oct 2009

CHA urges California Nurses Association to promote vaccinations to all health care workers

The California Hospital Association (CHA) is engaged with hospitals and state and local public health officials in a voluntary statewide effort to ensure that all hospital workers -- including registered nurses -- are vaccinated against the H1N1 flu virus.

21 Oct 2009

Bill & Melinda Gates Foundation's initiative to transform health in developing countries

The Bill & Melinda Gates Foundation today announced 76 grants of US$100,000 each to pursue bold ideas for transforming health in developing countries. The grants support researchers across 16 countries, including nine in Europe and Africa with ideas as diverse as using the power of sunlight to kill malaria-causing mosquito larvae and developing a device that repels mosquitoes without insecticides.

21 Oct 2009

Vaccine News and Research

Latest Vaccine News and Research

LANL and international researchers propose new genome sequence strategies

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

GlaxoSmithKline's CERVARIX recommended by CDC for protection against cervical cancer

Media outlets examine how AIDS vaccine trial results will shape future studies

Women more likely than men to curb swine flu

AIDS vaccine not as effective as first thought, scientists say

106m infants worldwide received vaccines last year, coverage gaps remain, report says

Research suggests latent cytomegalovirus infection exacerbates inflammatory bowel disease

EMEA informs Antigenics on a negative opinion for Oncophage MAA

Positive results from Argos Therapeutics' personalized immunotherapy candidate AGS-004 Phase 2a trial

Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain

Swine flu vaccines arrive at health departments, hospitals and community vaccinator facilities

Novavax, Xcellerex enter into collaboration to accelerate the development of Novavax's 2009 H1N1 vaccine

Professor secures grant for further research on immunotherapy strategies

Aethlon Hemopurifier effective in capturing H1N1 Swine Flu Virus

Weekly Digest releases report on investment opportunities in connection with the H1N1 outbreak

New public health tool to identify all Tier 1 candidates for H1N1 vaccination

Elan announces fiscal 2009 third-quarter results

CHA urges California Nurses Association to promote vaccinations to all health care workers

Bill & Melinda Gates Foundation's initiative to transform health in developing countries

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Vaccine News and Research

Latest Vaccine News and Research

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in